RBC Capital Increases Becton Dickinson & Co. Price Target to $113.00 (BDX)
Investment analysts at RBC Capital boosted their price target on shares of Becton Dickinson & Co. (NYSE:BDX) from $109.00 to $113.00 in a note issued to investors on Friday, Analyst Ratings Network.com reports. The firm currently has a “sector perform” rating on the stock. RBC Capital’s price target would suggest a potential downside of 3.72% from the stock’s previous close.
A number of other analysts have also recently weighed in on BDX. Analysts at Canaccord Genuity raised their price target on shares of Becton Dickinson & Co. from $108.00 to $110.00 in a research note on Friday, May 2nd. Separately, analysts at ISI Group raised their price target on shares of Becton Dickinson & Co. from $123.00 to $130.00 in a research note on Monday, April 7th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Becton Dickinson & Co. in a research note on Wednesday, March 26th. They now have a $120.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. Becton Dickinson & Co. currently has an average rating of “Hold” and a consensus price target of $107.43.
Becton Dickinson & Co. (NYSE:BDX) opened at 117.37 on Friday. Becton Dickinson & Co. has a 52-week low of $94.25 and a 52-week high of $118.77. The stock’s 50-day moving average is $114.3 and its 200-day moving average is $111.2. The company has a market cap of $22.655 billion and a P/E ratio of 24.31.
Becton Dickinson & Co. (NYSE:BDX) last released its earnings data on Thursday, May 1st. The company reported $1.45 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.50 by $0.05. The company had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.09 billion. During the same quarter last year, the company posted $1.39 earnings per share. Becton Dickinson & Co.’s revenue was up 3.6% compared to the same quarter last year. On average, analysts predict that Becton Dickinson & Co. will post $6.24 earnings per share for the current fiscal year.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.